High-density lipoprotein (HDL) has an impact on myeloma outcome: Lower HDL associates with worse progression-free survival.

Işıl Erdoğan Özünal Emrah Kılıçaslan Tayfun Elibol Erman Öztürk

Published in: Wiener klinische Wochenschrift (2023)

Myeloma patients have lower HDL than controls and HDL < 28 mg/dl associates with advanced-stage disease and shorter PFS. Therefore, HDL can be a surrogate prognostic marker in myeloma.

Keyphrases

newly diagnosed
high density
free survival
multiple myeloma
end stage renal disease
chronic kidney disease
ejection fraction
prognostic factors
patient reported outcomes